388 related articles for article (PubMed ID: 31551425)
21. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
22. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
Komiyama S; Numata K; Ogushi K; Moriya S; Fukuda H; Chuma M; Maeda S
Medicine (Baltimore); 2020 Jul; 99(29):e21191. PubMed ID: 32702881
[TBL] [Abstract][Full Text] [Related]
24. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
25. Review article: systemic treatment of hepatocellular carcinoma.
Pinter M; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
27. Molecular therapies for HCC: Looking outside the box.
Faivre S; Rimassa L; Finn RS
J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
[TBL] [Abstract][Full Text] [Related]
28. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
29. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J
Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Bekir Hacioglu M; Kostek O; Karabulut S; Tastekin D; Sezgin Goksu S; Alandag C; Akagunduz B; Bilgetekin I; Caner B; Bilgehan Sahin A; Yildiz B; Kose F; Kaplan MA; Gulmez A; Dogan E; Can Guven D; Gurbuz M; Ergun Y; Karaagac M; Gokcen Demiray A; Turker S; Sakalar T; Ozkul O; Telli TA; Sahin S; Kilickap S; Bilici A; Erdogan B; Cicin I
J BUON; 2020; 25(4):1897-1903. PubMed ID: 33099930
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
33. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
[TBL] [Abstract][Full Text] [Related]
34. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report.
Takeda K; Tsurumaru Y; Yamamoto Y; Araki K; Kogure Y; Mori K; Nakagawa K; Shimizu T; Matsuda G; Niino H; Sekido H; Kobayashi S; Morimoto M; Kunisaki C; Endo I
Clin J Gastroenterol; 2020 Jun; 13(3):428-433. PubMed ID: 31970661
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
[TBL] [Abstract][Full Text] [Related]
36. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
37. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
[TBL] [Abstract][Full Text] [Related]
38. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
39. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
[TBL] [Abstract][Full Text] [Related]
40. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
